logo-loader
viewAvalon GloboCare Corp

Avalon GloboCare successfully completes Phase I first-in-human clinical study of its leading Chimeric Antigen Receptor (CAR) T-cell therapy candidate

The group said that nine out of ten patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) achieved complete remission within one month after the initiation of AVA-001 CAR T-cell therapy treatment

Avalon GloboCare Corp -
Avalon GloboCare noted that treatment with AVA-001 was generally well tolerated with minimal toxicities and adverse side effects

Avalon GloboCare Corp. (NASDAQ:AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced that it has successfully completed Phase I first-in-human clinical study of its leading Chimeric Antigen Receptor (CAR) T-cell therapy candidate, AVA-001.

The group said that nine out of ten patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) achieved complete remission (CR) - a rate of 90% - within one month after the initiation of AVA-001 CAR T-cell therapy treatment.

READ: Avalon GloboCare forges partnership with Austrian university to develop coronavirus vaccine

It noted that treatment with AVA-001 was generally well tolerated with minimal toxicities and adverse side effects. No neurotoxicity or greater than Grade-1 cytokine release syndrome was observed in this cohort of patients treated with AVA-001. All patients who achieved CR successfully proceeded to allogeneic bone marrow transplant with curative intent.

AVA-001 is a third-generation CAR T-cell therapy which involves the 4-1BB (or CD28) co-stimulation signaling pathway. Accessary laboratory testing that accompanied this pilot clinical study has demonstrated evidence of enhancement in CAR T cell persistence and protection against CAR T cell exhaustion.

Avalon GloboCare said it will present the results of this AVA-001 Phase 1 clinical trial on July 11,2020 at The Eighth Annual Lu Daopei Hematology Forum, the largest Hematology Conference in Asia, which will be held online according to the organizer due to the coronavirus (COVID-19) pandemic.

David Jin, president and chief executive officer of Avalon GloboCare commented: “We are excited and pleased to achieve these successful outcomes with our AVA-001 CAR T-cell therapy. This paradigm of bridging CAR T-cell therapy to bone marrow transplant creates a new therapeutic horizon with curative potential for patients with relapsed/refractory B-ALL and other hematologic cancers.”

Avalon GloboCare is a clinical-stage, vertically-integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. It also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets.

Quick facts: Avalon GloboCare Corp

Price: 1.74 USD

NASDAQ:AVCO
Market: NASDAQ
Market Cap: $138.09 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Avalon GloboCare Corp named herein, including the promotion by the Company of Avalon GloboCare Corp in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Avalon Globocare Corp seeing success working in the celltech space

Avalon GloboCare CEO (NASDAQ:AVCO) Dr. David Jin sat down with Proactive's Steve Darling at the 12th annual LD Micro Conference. The company is a clinical-stage CellTech bio-developer specializing in cellular therapeutics. Dr Jin talked about success in 2019 and what he expects in 2020.

on 12/10/2019

2 min read